Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + epirubicin
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral (anlotinib), Intravenous (epirubicin)
01
Overview
**Anlotinib + epirubicin** is a combination therapy of two small molecule drugs used investigationally for the first-line treatment of advanced or metastatic soft tissue sarcoma (STS)[1][2][3][5][7].\n- **Anlotinib** is a selective multi-kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit, thereby inhibiting tumor angiogenesis and cell proliferation[1][7].\n- **Epirubicin** is an anthracycline chemotherapeutic agent that intercalates into DNA and inhibits topoisomerase II, leading to the inhibition of DNA replication and repair, and induces cell death.\nThe combination has shown synergistic activity both in patient-derived xenograft (PDX) models and in patients, with improved efficacy and a tolerable safety profile relative to historic controls[1][2][3][5][7]. The primary indication studied is unresectable locally advanced or metastatic soft tissue sarcoma, with phase II clinical trial evidence suggesting improved progression-free survival over chemotherapy alone[1][2][3][5].
- Other names
- anlotinib plus epirubicinanlotinib and epirubicin
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TOP2A (DNA topoisomerase II)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on anlotinib + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + epirubicin.